Description:
Rocilinostat is an orally bioavailable histone deacetylase 6 (HDAC6) inhibitor with potential antineoplastic activity. It selectively targets and binds to HDAC6, thereby disrupting the Hsp90 protein chaperone system through hyperacetylation of Hsp90 and preventing the subsequent aggresomal protein degradation. Compared to non-selective HDAC inhibitor, Rocilinostat is able to reduce the toxic effects on normal, healthy cells.
- Molecular Weight: 433.512
- Molecular Formula: C24H27N5O3
Purity: 98%
Canonical SMILES:
C1=CC=C(C=C1)N(C2=CC=CC=C2)C3=NC=C(C=N3)C(=O)NCCCCCCC(=O)NO
InChI:
InChI=1S/C24H27N5O3/c30-22(28-32)15-9-1-2-10-16-25-23(31)19-17-26-24(27-18-19)29(20-11-5-3-6-12-20)21-13-7-4-8-14-21/h3-8,11-14,17-18,32H,1-2,9-10,15-16H2,(H,25,31)(H,28,30)
InChIKey: QGZYDVAGYRLSKP-UHFFFAOYSA-N
- Appearance: White to Off-white Solid Powder
- Application: Antineoplastic Agents
Synonyms:
ACY-1215; ACY1215; ACY 1215; Rocilinostat; 2-(Diphenylamino)-N-(7-(hydroxyamino)-7-oxoheptyl)pyrimidine-5-carboxamide
More details are to be found on supplier website
